Literature DB >> 7714951

Long-term renal fate and prognosis after staghorn calculus management.

J M Teichman1, R D Long, J C Hulbert.   

Abstract

We analyzed retrospectively 177 consecutive staghorn calculus patients to determine risk factors for ultimate renal deterioration and renal cause specific death. Mean followup was 7.7 years. Overall rate of renal deterioration was 28%. Renal deterioration was associated more frequently among patients with solitary versus nonsolitary kidneys (77% versus 21%, p < 0.001), previous versus initial stones (39% versus 14%, p = 0.03), recurrent versus nonrecurrent calculi (39% versus 22%, p = 0.07), hypertension versus normotension (50% versus 22%, p = 0.006), complete versus partial staghorn calculi (34% versus 13%, p = 0.02), diversion versus no diversion (58% versus 19%, p < 0.001) and neurogenic bladder versus normal voiding (47% versus 21%, p = 0.006), as well as those who refused treatment versus treated patients (100% versus 28%, p < 0.001). No patient with complete clearance of fragments died of renal related causes compared to 3% of those without clearance of fragments and 67% of those who refused treatment (p < 0.001). Our study suggests that long-term renal preservation in the staghorn calculus patient may depend on normal blood pressure, staghorn size, absence of diversion or voiding dysfunction, and complete stone eradication.

Entities:  

Mesh:

Year:  1995        PMID: 7714951

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Minimally invasive percutaneous nephrolithotomy with multiple mini tracts in a single session in treating staghorn calculi.

Authors:  Wen Zhong; Guohua Zeng; Wenqi Wu; Wenzhong Chen; Kaijun Wu
Journal:  Urol Res       Date:  2010-09-07

2.  Evaluating factors that dictate struvite stone composition: A multi-institutional clinical experience from the EDGE Research Consortium.

Authors:  Ryan K Flannigan; Andrew Battison; Shubha De; Mitchell R Humphreys; Markus Bader; Ekaterina Lellig; Manoj Monga; Ben H Chew; Dirk Lange
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

3.  Large stone burden in a congenital solitary pelvic kidney.

Authors:  Vincent G Bird; John M Shields
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 4.  Renal struvite stones--pathogenesis, microbiology, and management strategies.

Authors:  Ryan Flannigan; Wai Ho Choy; Ben Chew; Dirk Lange
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

Review 5.  Stone formation and management after bariatric surgery.

Authors:  Sarah Tarplin; Vishnu Ganesan; Manoj Monga
Journal:  Nat Rev Urol       Date:  2015-04-07       Impact factor: 14.432

Review 6.  Percutaneous nephrolithotomy: complications and how to deal with them.

Authors:  Daniel A Wollin; Glenn M Preminger
Journal:  Urolithiasis       Date:  2017-11-17       Impact factor: 3.436

Review 7.  Role of conservative management of stones.

Authors:  Kesavapillai Subramonian; Hector Sandoval Barba; Maitrey Darrad
Journal:  Turk J Urol       Date:  2020-11-01

8.  Conservative management of staghorn stones.

Authors:  M Alsawi; T Amer; M Mariappan; S Nalagatla; A Ramsay; O Aboumarzouk
Journal:  Ann R Coll Surg Engl       Date:  2020-01-10       Impact factor: 1.891

9.  Endoscopic and Pathologic Characterization of Papillary Architecture in Struvite Stone Formers.

Authors:  Christopher D Jaeger; Andrew D Rule; Ramila A Mehta; Lisa E Vaughan; Terri J Vrtiska; David R Holmes; Cynthia M McCollough; Matthew J Ziegelmann; Loren P Herrera Hernandez; John C Lieske; Amy E Krambeck
Journal:  Urology       Date:  2016-01-06       Impact factor: 2.649

10.  Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota.

Authors:  Nathan A Saucier; Mukesh K Sinha; Kelly V Liang; Amy E Krambeck; Amy L Weaver; Eric J Bergstralh; Xujian Li; Andrew D Rule; John C Lieske
Journal:  Am J Kidney Dis       Date:  2009-10-22       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.